SALEM, Mass., April 14 /PRNewswire/ -- LaVoie Group, a full-service provider of public relations, investor relations, corporate communications, and marketing strategy to life science clients, today announced that it has been selected as public relations agency of record by Interleukin Genetics (Amex: ILI).
Donna L. LaVoie, President & CEO, commented, "With personalized medicine top of mind across a number of different constituencies, Interleukin Genetics is well positioned to capitalize on its strengths in genetics research to develop a series of innovative preventive products. LaVoie Group looks forward to continue helping Interleukin communicate its story."
Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
About LaVoie Group
LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position create visibility and drive value for each client. Our clients range from private start-ups to industry leaders in life sciences. For more information, please visit www.lavoiegroup.com.
SOURCE LaVoie Group